Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus +/- Pasireotide LAR in Advanced PNET
NCT01374451Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Feb 2015
- Modality
- Peptides, Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial of pasireotide LAR in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free Survival at 24 months. Started Jun 2011; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01374451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374451.